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a	 deletion	mutant,	GPNMB(ΔKLD).	 Enhanced	 expression	 of	WT	GPNMB	 induced	
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toma,	 and	breast	 cancer.	 It	 is	 considered	a	poor	prognostic	 factor	
in	those	cancers	and	it	might	be	an	attractive	therapeutic	target.1‐5
We	have	previously	reported	that	enhanced	expression	of	GPNMB	



























2  | MATERIAL S AND METHODS





expressing	GPNMB,	 both	WT	 and	KLD‐deletion	mutant	 (ΔKLD),	
were	maintained	 in	 the	presence	of	puromycin	 (1	μg/mL;	Sigma‐
Aldrich).6	L	Wnt‐3A	cells	and	L	cells	(ATCC)	were	used	to	prepare	
Wnt3A	 conditioned	 medium	 and	 control	 medium	 as	 described	
previously.20
2.2 | DNA constructs and transfection
Glycoprotein	NMB	 and	 Src	 cDNA	were	 cloned	 previously,6 and 
GPNMB(ΔKLD)	 lacking	 amino	 acids	 420‐491	of	mouse	GPNMB	
was	 generated	 by	 PCR,	 followed	 by	 cloning	 into	 pCAGIP‐	 or	
pcDEF3‐expressing	 vectors.	 pCAG‐GS‐β‐catenin	 and	 TOP‐flash	
luciferase	reporter	were	described	previously.20	These	constructs	
were	transfected	 into	cells	by	use	of	PEI	Max	 (Polysciences).	To	
establish	 stably	 expressing	 cell	 lines,	NMuMG	cells	were	 trans‐







precipitated	by	 centrifugation;	 a	 small	 amount	of	 total	 cell	 lysates	
was	collected	and	the	remainder	was	used	for	immunoprecipitation	
with	anti‐FLAG	Ab	(M2;	Sigma‐Aldrich).
2.4 | Sodium dodecyl sulfate‐PAGE and 
immunoblot analysis
The	 protein	 samples	 were	 subjected	 to	 SDS‐PAGE.	 The	 proteins	
were	 then	 electrotransferred	 to	 PVDF	 membranes	 (Millipore)	
and	 subjected	 to	 immunoblot	 analysis.	 Antibodies	 against	 FLAG	
(M2;	 Sigma‐Aldrich),	HA	 (3F10;	 Roche	Diagnostics),	 c‐Myc	 (9E10;	





with	 trypsin	 (Sigma)	 to	 yield	 single	 cells.	 The	 floating	 single	 cells	
were	 incubated	 with	 anti‐GPNMB	 Ab	 (AF2550;	 R&D	 Systems),	




2.6 | Reverse transcription‐PCR and quantitative 
real‐time PCR
Reverse	 transcription‐PCR	 (RT‐PCR)	 was	 carried	 out	 as	 de‐
scribed	 previously.23	 In	 brief,	 total	 RNA	 was	 extracted	 using	
ISOGEN	 II	 reagent	 (Nippon	 Gene).	 Reverse	 transcription	 was	
undertaken	 using	 High	 Capacity	 RNA‐to‐cDNA	 Master	 Mix	
(Applied	 Biosystems)	 and	 semiquantitative	 RT‐PCR	 was	 car‐
ried	 out	 with	 the	 previously	 described	 specific	 primers6 and 
using	 Ex	 Taq	 polymerase	 (Takara).	 Real‐Time	 PCR	 was	 per‐
formed	using	GeneAce	 SYBR	quantitative	 real‐time	PCR	 (qPCR)	
mix	α	 Low	ROX	 (Nippon	Gene)	 and	 the	ABI7500	Fast	Sequence	
Detection	 system	 (Applied	Biosystems).	All	 samples	were	 run	 in	
triplicate	 in	 each	 experiment.	 Primer	 sequences	 are	 as	 follows:	
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mouse Axin2	 forward,	 5′‐TGACTCTCCTTCCAGATCCCA‐3′,	
and	 reverse	 5′‐TGCCCACACTAGGCTGACA‐3′);	 and	 mouse	 β‐
actin	 forward,	 5′‐CGATGCCCTGAGGCTCTTT‐3′,	 and	 reverse	
5′‐TGGATGCCACAGGATTCCA‐3′.
2.7 | Sphere formation
A	 total	 of	 5	 ×	 103	 NMuMG‐mock,	 NMuMG‐GPNMB(WT),	 or	
NMuMG‐GPNMB(ΔKLD)	 cells	 were	 cultured	 in	 DMEM/F12	
medium	 (Sigma‐Aldrich)	 supplemented	 with	 20	 μL/mL	 B27	






A	 total	 of	 1	 ×	 107	 NMuMG‐mock,	 NMuMG‐GPNMB(WT),	 or	
NMuMG‐GPNMB(ΔKLD)	 cells	 were	 injected	 s.c.	 into	 6‐week‐
old	 female	 ICR‐	nu/nu	mice	 (Clea	 Japan).	 The	mice	were	 killed,	
and	 the	 tumor	 grafts	 harvested	 at	 8	 weeks	 postinjection.	 The	
tumor	volumes	were	approximated	using	the	following	formula:	






Tsukuba	 and	 in	 accordance	with	 the	 university's	 animal	 experi‐
ment	 guidelines	 and	 the	 provisions	 of	 the	 1995	Declaration	 of	
Helsinki.
2.9 | Transwell migration assay








The	cells	were	 fixed	 in	4%	paraformaldehyde.	After	 fixation,	we	
incubated	 the	 cells	 using	 PBS	 supplemented	with	 0.3%	 Triton‐X	
and	1%	BSA	for	cell‐membrane	permeabilization	and	blocking.	The	
primary	Abs	used	were	against	GPNMB	(AF2550;	R&D	Systems),	
LAMP1	 (Cell	 Signaling	 Technology),	 and	 EEA1	 (Cell	 Signaling	
Technology).	The	 reacted	Abs	were	detected	with	 fluorescence‐
conjugated	 anti‐rabbit	 IgG	 (Alexa	 Fluor	 568;	 Molecular	 Probes)	
and	 fluorescence‐conjugated	 anti‐goat	 IgG	 (Alexa	 Fluor	 488;	
Molecular	Probes).	TO‐PRO3	(Thermo	Fisher	Scientific)	was	used	
for	nuclear	staining.	For	the	actin	staining,	fluorescein	phalloidin	




The	 paraffin‐embedded	 tissue	 sections	 were	 deparaffinized	 in	




the	 samples	were	 incubated	with	Abs	against	HA	 (3F10;	Roche	
Diagnostics),	 E‐cadherin	 (610181;	 BD	 Biosciences),	 and	 Ki‐67	
(Abcam).	After	 the	 sections	 had	been	washed,	 the	 reacted	Abs	
were	 detected	 using	 the	 Dako	 EnVision+	 System/HRP	 (DAB)	
(DakoCytomation).
2.12 | Transmission electron microscopy











homology	of	 the	 sequences.	 The	 alignment	 results	were	obtained	
using	the	MegAlign	program	with	the	Jotun	Hein	method.
2.14 | Luciferase reporter assay
Cells	 were	 transfected	 with	 the	 TOP‐flash	 firefly	 luciferase	 re‐
porter	and	pRL‐CMV	Renilla	luciferase	reporter.	Luciferase	activ‐
ity	 in	cell	 lysates	was	determined	by	a	Luciferase	reporter	assay	
system	 (Promega)	using	a	 luminometer	 (MicroLumat).	 Luciferase	





comparison	 test	 with	 GraphPad	 Prism	 7	 software	 (GraphPad)	 or	
Student's	t	test	with	Excel	(Microsoft).	Probability	values	<0.05	were	
considered	significant.
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3  | RESULTS
3.1 | Glycoprotein NMB has a KLD that is conserved 
across species
To	 identify	the	 important	region	 in	the	ECD	of	GPNMB	in	terms	





a	KD	contains	80	amino	acids	and	 its	 typical	 loop	structures	are	
formed	by	3	 intramolecular	disulfide	bonds.24	We	first	examined	




3.2 | Deletion of the KLD does not affect GPNMB 
subcellular localization, tyrosine phosphorylation, or 
homo‐oligomer formation
To	 investigate	 the	 function	 of	 the	 KLD	 in	 GPNMB,	 we	 con‐
structed	a	deletion	mutant	of	mouse	GPNMB,	GPNMB(ΔKLD)	in	








(here	 called	 G3	 and	 G86)	 and	 NMuMG‐GPNMB(ΔKLD)	 clone	 7	
and	 clone	11	 (here	 called	ΔKLD7	and	ΔKLD11)	 (Figure	2D).	We	
next	undertook	immunofluorescence	staining	to	examine	the	sub‐














the	deletion	of	 the	KLD	does	not	 affect	 the	basic	 properties	of	
GPNMB,	 such	 as	 subcellular	 localization,	 tyrosine	 phosphoryla‐
tion,	 and	homo‐oligomer	 formation.	Therefore,	we	continued	 to	
investigate	the	tumorigenic	functions	of	GPNMB(ΔKLD).















     |  2241XIE Et al.
2242  |     XIE Et al.
3.3 | Kringle‐like domain is important in GPNMB‐
induced tumorigenic potential
To	 investigate	 the	 importance	 of	 the	 KLD	 in	 GPNMB‐induced	 tumo‐
rigenic	growth,	we	undertook	assays	of	in	vitro	sphere	formation	and	in	
vivo	 tumor	 formation.	 GPNMB(ΔKLD)‐expressing	 cells	 showed	 signifi‐
cantly	lower	sphere‐forming	activity	than	that	of	GPNMB(WT)‐expressing	






3.4 | Deletion of the KLD partially maintains cellular 
junctions and polarity
We	 next	 analyzed	 each	 tumor	 histologically.	 On	 H&E	 staining,	 tu‐
bular	 structures	 were	 observed	 in	 the	 tissue	 of	 the	 NMuMG‐mock	














GPNMB(WT)‐expressing	 cells,	 the	 GPNMB(ΔKLD)‐expressing	 cells	




















F I G U R E  3  Deletion	of	the	kringle‐like	domain	(KLD)	attenuates	the	tumorigenic	ability	of	glycoprotein	NMB	(GPNMB).	A,	Sphere‐
forming	abilities	of	NMuMG‐mock,	NMuMG‐GPNMB(WT)	(G3	and	G8),	and	NMuMG‐GPNMB(ΔKLD)	(∆K7	and	∆K11)	cells	were	
examined.	Only	spheres	larger	than	50	μm	in	diameter	were	counted.	Data	are	presented	as	mean	±	SD;	n = 3	replicates,	representative	of	3	
independent	experiments.	**P < 0.01,	****P < 0.0001	(vs	mock),	#P < 0.05,	####P < 0.0001	(vs	G3	and	G8),	1‐way	ANOVA	with	Tukey	multiple	
comparison	test.	B,C,	Tumor	growth	abilities	of	NMuMG‐mock,	NMuMG‐GPNMB(WT)	(G8),	and	NMuMG‐GPNMB(ΔKLD)	(∆K7	and	∆K11)	
cells	examined	by	s.c.	injection	into	ICR‐nu/nu	mice.	Macroscopic	view	(B)	and	measured	volumes	(C).	Data	are	presented	as	mean	±	SD;	n = 5	
mice.	****P < 0.0001	(vs	mock),	####P < 0.0001	(vs	G8),	1‐way	ANOVA	with	Tukey	multiple	comparison	test
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GPNMB(ΔKLD)	 grafts	with	 the	mock	 grafts.	 Tight	 junctions	were	
observed	 in	 the	mock	 grafts,	whereas	 none	 could	 be	 observed	 in	
the	GPNMB(WT)	 grafts;	 in	 addition,	 no	 villi	 could	 be	 observed	 in	





3.5 | Deletion of the KLD maintains the GPNMB 
function to suppress E‐cadherin expression but 
impairs its function to activate cellular migration and 
Wnt/β‐catenin signaling
We	 further	 examined	 the	 phenotypes	 of	 GPNMB(ΔKLD)	 cells	 in	
terms	of	the	induction	of	EMT.	Previously,	we	reported	that	enhanced	
expression	 of	 GPNMB(WT)	 induces	 EMT	 phenotypes	 in	 NMuMG	
cells,	such	as	downregulation	of	E‐cadherin,	promotion	of	cellular	mi‐




fiber	 formation,	whereas	 GPNMB(ΔKLD)	 retained	 the	 cortical	 actin	







cell	migration‐inducing	 activity	of	GPNMB	has	not	been	 fully	 eluci‐
dated	yet,	but	our	preliminary	examination	indicated	the	impairment	



























was	 not	 observed	 in	 the	 NMuMG‐GPNMB(WT)	 tumor	 (Figure	 4A,B).	
Tight	 junctions	are	associated	with	maintenance	of	cell	polarity;	there‐
fore,	 these	 results	might	 explain	why	GPNMB(ΔKLD)‐expressing	 cells	
partially	retain	cell	polarity	when	compared	with	GPNMB(WT).
We	 previously	 reported	 that	 expression	 of	 GPNMB(WT)	 fully	
induces	EMT	in	NMuMG	cells.6	In	the	current	study,	we	have	con‐
firmed	 that	 overexpression	 of	 GPNMB(ΔKLD)	 suppressed	 E‐cad‐
herin	expression	at	both	the	mRNA	and	the	protein	 levels,	as	well	
as	GPNMB(WT)	did	 (Figure	5A,B).	 In	contrast,	GPNMB(ΔKLD)	did	
not	 induce	 stress	 fiber	 formation	nor	 cell	migration	 (Figure	5C,D).	
Epithelial‐mesenchymal	transition	is	a	biological	process	that	allows	
epithelial	 cells	 to	 harbor	 mesenchymal	 phenotypes,	 which	 acti‐
vates	cell	migration,	 invasiveness,	and	resistance	to	apoptosis,	and	
also	 contributes	 to	 induction	 of	 stem‐like	 properties.25‐27	 During	
EMT,	dissolution	of	 adherence	 junction	proteins	 and	disruption	of	
the	tight	junctions	lead	the	cells	to	lose	their	cell‐cell	adhesion	and	
apical‐basal	polarity,	and	thus,	they	become	migratory	and	invasive.	
However,	 sometimes	 it	 is	not	easy	 to	divide	cancer	cells	 into	cells	
with	 only	 epithelial	 or	mesenchymal	 features,	 and	 cells	with	 both	
epithelial	 and	 mesenchymal	 phenotypes	 have	 recently	 been	 re‐
ported,	which	is	termed	partial	EMT.28,29	Although	the	phenotypes	
of	 NMuMG‐GPNMB(ΔKLD)	 are	 different	 from	 those	 of	 complete	
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EMT	and	partial	EMT,	it	might	be	a	kind	of	intermediate	phenotype	
between	epithelial	 and	mesenchymal,	 resulting	 in	 fewer	migratory	
and	tumorigenic	abilities.
The	point	mutant	in	which	the	tyrosine	residue	in	hemITAM	was	
altered	 to	 phenylalanine,	GPNMB(YF),	 totally	 lost	 EMT	 and	 stem‐
like	 properties	 inducing	 activity.6,7	 GPNMB(YF)	 did	 not	 suppress	
E‐cadherin	 and	 lacked	 the	 promoting	 effect	 on	 cellular	 migration	
and	sphere	and	tumor	formation,6	indicating	the	crucial	role	of	the	
tyrosine	 residue	 in	 the	 tumorigenic	 ability	 of	 GPNMB.	 However,	
















to	be	 responsible	 for	Wnt	 ligand	binding,	 in	 their	ECD.	Wnt5A	 in‐
duces	 ROR1	 and	 ROR2	 heterodimerization	 through	 KD,	 and	 acti‐
vates	chemotaxis	and	proliferation	of	leukemia	cells.35	Additionally,	
MuSK	is	also	involved	in	the	noncanonical	Wnt	signaling	pathway.36 








of	 the	 binding	 partner	 through	 this	 region	 is	 essential.	 The	Wnt/
PCP	 pathway	 must	 be	 the	 focus	 in	 studies	 of	 the	 phenotype	 of	
GPNMB(ΔKLD)	cell	tumors	in	the	future.
Glembatumumab	 vedotin,	 or	CDX‐011,	 an	Ab	 against	GPNMB	
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